Cingulate (NASDAQ:CINGW – Get Free Report) will likely be announcing its results before the market opens on Wednesday, November 18th. Analysts expect Cingulate to post earnings of ($0.4325) per share and revenue of $0.54 million for the quarter.
Cingulate Stock Down 2.5%
Cingulate stock opened at $0.00 on Wednesday. Cingulate has a 52-week low of $0.00 and a 52-week high of $0.12. The firm’s fifty day moving average is $0.01 and its 200 day moving average is $0.02.
About Cingulate
Cingulate is a clinical-stage biopharmaceutical company developing prescription treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company’s development programs are based on its proprietary Precision Timed Release (PTR) drug-delivery platform. Its ADHD candidates include CTx-1301, which uses dexmethylphenidate, and CTx-1302, which uses d-amphetamine. The formulations are designed to release medication in separate phases after a single morning dose, with the goal of providing extended symptom control throughout the day.
Read More
- Five stocks we like better than Cingulate
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
